Aaron Johnson is the Vice President of Marketing & Customer Strategy and a part of the technical sales team at Accumold. He is recognized as a leader on the subject on micro injection molding and has developed and presented numerous technical presentations and has been published in many industry trade publications. He has been with Accumold since 2005 and currently finishing his Master's in Business Administration.
Amber is an entrepreneur with a broad variety of skills with 24 years experience. She has led 3 previous business to successful exits. She is an out of the box thinker, can do and go for it mentality. Amber is the inventor of EPIWatch and owner of the concept patent and the mechanical patent.
Benedikt acts as the first point of contact for pharmaceutical companies planning the outsourcing of manufacturing of sterile liquid pharmaceuticals at Fresenius Kabi’s manufacturing sites in Europe and Asia. Benedikt joined Fresenius Kabi as a Management Trainee after completing his PhD in Organic Chemistry from the Karl-Franzens University of Graz, Austria in 2014. He afterwards covered the role of executive assistant at Fresenius Kabi focusing on pharmaceutical manufacturing, global investments, strategy roll-out, capacity and supply chain management.
After studying chemical Engineering and Business Management, Cecile Balloffet joined Clariant in 2006. After being an area sales manager, Cecile joined the team of newly formed Healthcare Polymers Solutions segment which focuses on enhancing and protecting healthcare products.
She initiates and manages new business developments in Western Europe. Born of the collective strength of PolyOne & Clariant Masterbatches since July 1st 2020, Avient is a leading provider of plastics colors & additives.
Dr. Clemens Günther received his diploma in biology and doctorate for natural sciences from the Free University, Berlin-Germany. Dr. Günther has gained over 30 years experience in drug development. He has been involved in nonclinical development and regulatory toxicology of small molecules, biologics, medical devices and drug device combination products.
Jakob is an Engineer and Materials Scientist by training with an MSc degree in Chemical Engineering from the Royal Institute of Technology in Stockholm, Sweden and a PhD in Polymer Science from the Swiss Federal Institute of Technology in Lausanne, Switzerland. He has written and published close to 40 peer-reviewed papers on medical devices, packaging materials and polymers and is a regular contributor to technical and scientific conferences.
Dr Joël Richard is currently Chief Development Officer at MedinCell (Montpellier, France). He is leading all the drug development activities of the company, based on the proprietary technology BEPO® for Long-Acting Injectables. (LAIs). These activities comprise formulation and process development, device development, analytical development, process transfer and scale-up, manufacturing and supply of clinical batches, regulatory affairs, non-clinical and clinical development operations, quality and regulatory compliance.
Min is a Director and Fellow at Astrazeneca. He has over 15 years of pharmaceutical product development experience. Prior to AstraZeneca, Min worked at Johnson&Johnson, BD and Eli Lilly and on projects from concept phase through commercialization. His experience spans formulation development, device engineering, process engineering and packaging development. Currently, Min is focusing on parenteral product development, including new modalities, such as cell and gene therapy.
Prior to this position, he was Deputy Head of Sales and Area Sales Manager for the USA at Seidenader in Markt Schwaben, also a Körber Group company.
As Area Sales Manager at Seidenader, Peter Grassl played a significant role in the company's success in the US market and therefore an important role in the company's overall growth.
Dr Ramin Rafiei is the Director of Digital Healthcare at SHL Medical. As the architect of digital health at SHL Medical, Ramin has built across SHL and partners the vision and capacity to formulate, build, commercialize, validate and scale innovations in digital medicine and virtual care. Ramin’s multidisciplinary approach to digital health originates from a dynamic career leading global high-stake technical and commercial initiatives across aerospace, nuclear, photonics and autonomous-technology industries.
ené Holm received his pharmaceutical training at the Royal Danish School of Pharmacy, now the school of pharmacy at University of Copenhagen, Denmark, in 1998 and his PhD in biopharmaceutics from the same institution in 2002. Dr. Holm joined Lundbeck in 2001 and changed to Janssen in 2016. Dr. Holm has worked within pharmaceutical development, formulations for non-clinical testing in drug discovery, physical chemistry and material science covering both small and large molecules and is now responsible for the functional unit ensuring development of all non-solid formulations for Janssens small molecule value stream.
Tudor Arvinte, Ph.D., received his academic training in physics at the University of Jassy, Romania, and his Ph.D. in biophysics from the University of Düsseldorf, Germany. He performed his doctoral work and postdoctoral stage at the Max-Planck-Institute West Germany and held numerous research positions in Europe and the USA: at C.N.R.S., Orléans, France, at Cornell University, New York, at Texas A&M University, and at the Biophor Corporation, College Station, Texas, USA.